Literature DB >> 24062392

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity.

Natalia Rompoti1, Bastian Schilling, Elisabeth Livingstone, Klaus Griewank, Uwe Hillen, Wolfgang Sauerwein, Christoph Pöttgen, Martin Stuschke, Dirk Schadendorf, Lisa Zimmer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24062392     DOI: 10.1200/JCO.2013.50.8473

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia.

Authors:  Nina Lang; Florian Sterzing; Alexander H Enk; Jessica C Hassel
Journal:  Strahlenther Onkol       Date:  2014-06-28       Impact factor: 3.621

2.  [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Authors:  R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

3.  Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.

Authors:  Amparo Wolf; Sayyad Zia; Rashika Verma; Anna Pavlick; Melissa Wilson; John G Golfinos; Joshua S Silverman; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2016-02-06       Impact factor: 4.130

Review 4.  Targeted Treatment of Brain Metastases.

Authors:  Nicole Shonka; Vyshak Alva Venur; Manmeet S Ahluwalia
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

5.  Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

Authors:  Maikel Verduin; Jaap D Zindler; Hanneke M A Martinussen; Rob L H Jansen; Sander Croes; Lizza E L Hendriks; Danielle B P Eekers; Ann Hoeben
Journal:  Oncologist       Date:  2017-02-06

Review 6.  Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review.

Authors:  Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff
Journal:  Cancer Metastasis Rev       Date:  2021-01-04       Impact factor: 9.264

Review 7.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

Review 8.  [Melanoma brain metastases : Treatment options].

Authors:  R Rauschenberg; G Tabatabai; E G C Troost; M Garzarolli; S Beissert; F Meier
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

9.  Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib.

Authors:  Sara Valpione; Luca G Campana; Jacopo Pigozzo; Vanna Chiarion-Sileni
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

10.  Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?

Authors:  Daniela Alterio; Giulia Marvaso; Annamaria Ferrari; Ombretta Alessandro; Emilia Cocorocchio; Pier Francesco Ferrucci; Roberto Orecchia; Barbara Alicja Jereczek-Fossa
Journal:  BJR Case Rep       Date:  2016-05-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.